Search the Newsreel

Entrada Therapeutics (NASDAQ:TRDA) Major Shareholder Ventures L.P. 5Am Sells 10,494 Shares

Insider Selling: Entrada Therapeutics (NASDAQ:TRDA) Director Sells $358,371.45 in Stock

Entrada Therapeutics (NASDAQ:TRDA) Director Kush Parmar sold 52,317 shares of the company's stock for $358,371.45 on August 7th, reducing his ownership by 1.84%. This sale is part of a series of recent transactions by Parmar, totaling significant amounts in August and July. The company's …

5am Ventures V, L.P. sells $431,829 of Entrada Therapeutics stock By Investing.com

5am Ventures V, L.P., a major stakeholder in Entrada Therapeutics Inc. (NASDAQ:TRDA), sold $431,829 worth of common stock across multiple transactions on August 6 and 7, 2026, with prices ranging from $6.85 to $7.00 per share. Despite the stock's year-to-date decline, InvestingPro analysis suggests …

Entrada Therapeutics (TRDA): 5AM Ventures-linked funds sell 62,811 shares, retain over 1.09M

Investment funds associated with 5AM Ventures, a major stockholder in Entrada Therapeutics (TRDA), sold a total of 62,811 shares of common stock on August 6-7, 2026. The sales were executed at weighted average prices of $7.00 and $6.85 per share. Following these transactions, an …

Entrada Therapeutics Inc (TRDA) Stock News Today

Entrada Therapeutics Inc (TRDA) Earnings Forecast: Future EPS & Revenue Growth Estimates

Entrada Therapeutics earnings beat by $0.04, revenue fell short of estimates

Entrada Therapeutics Releases Q2 2026 Financial Results

Entrada Therapeutics, Inc. reported a net loss of $42.8 million for the first half of 2026, reflecting continued investment in its pipeline of intracellular therapeutics. The company posted a loss of $1.01 per share, with revenue totaling $898,000, a 54.0% decrease from H1 2025. …

Entrada Therapeutics, Inc. (TRDA) Stock Price, News, Quote & History

This page provides comprehensive financial data for Entrada Therapeutics, Inc. (TRDA), a clinical-stage biopharmaceutical company. It includes real-time stock price, historical data, key statistics, performance overview against the S&P 500, earnings trends, analyst insights, and valuation measures. The company focuses on developing genetic medicines …

Entrada Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary

Entrada Therapeutics, Inc. has released its earnings summary for the quarter that ended on June 30. The brief report indicates the company's financial performance for the specified period. The full details are available through Refinitiv and other news sources on TradingView.

Entrada Therapeutics (NASDAQ: TRDA) details $82M H1 loss and $223M cash runway

Entrada Therapeutics reported a net loss of $42.8 million for Q2 2026 and $82.5 million for the first half of 2026, with collaboration revenue declining due to the completion of major research milestones. The company maintains a strong cash position of $223.0 million, expected …

Entrada Therapeutics publishes corporate presentation on genetic medicines pipeline for neuromuscular and inherited retinal diseases

Entrada Therapeutics announced upcoming clinical data catalysts for 2026 across Duchenne muscular dystrophy and myotonic dystrophy type 1. The company's ENTR-601-44 Phase 1/2 Cohort 1 showed significant improvement in Time to Rise and no serious adverse events. Future data releases include Cohort 1 open-label …

Entrada Therapeutics, Inc. (TRDA) Reports Q2 Loss, Tops Revenue Estimates

Entrada Therapeutics, Inc. (TRDA) reported a narrower-than-expected Q2 loss of $1.01 per share, beating the Zacks Consensus Estimate of a $1.16 loss. The company also surpassed revenue estimates, posting $0.9 million for the quarter, although this was lower than the $1.95 million reported a …

Entrada Therapeutics (Nasdaq: TRDA) reports Q2 2026 results and sets DMD, DM1 data timeline

Entrada Therapeutics (TRDA) reported a Q2 2026 net loss of $42.8 million and outlined upcoming clinical milestones for its Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1) programs. The company held $223.0 million in cash, expected to fund operations into Q3 2027, …

Entrada Therapeutics reports Q2 2026 results: $223.0M cash; Q2 net loss $42.8M

Entrada Therapeutics reported its second-quarter 2026 financial results, showing a net loss of $42.8 million and cash, cash equivalents, and marketable securities totaling $223.0 million. The company expects its cash reserves to fund operations into Q3 2027. Entrada also provided updates on its clinical …

Entrada Therapeutics, Inc. 2026: Revenue $898K, EPS ($1.01) — 10-Q Summary

Entrada Therapeutics, Inc. reported its Q2 2026 results, showing collaboration revenue of $898K and a diluted loss per share of ($1.01). The company highlighted clinical advancements in its DMD programs, progress in its collaboration with Vertex, and an expected funding runway into Q3 2027 …

Entrada Therapeutics director, 10% owner Kush Parmar disposes of $807,529 in common shares

Entrada Therapeutics director and 10% owner Kush Parmar sold 116,474 common shares on July 30-31, totaling $807,529. These transactions reduced 5AM Ventures V's stake to 2,846,592 shares, while 5AM Opportunities I held 1,093,313 shares afterward. This news brief was generated by AI based on …

Entrada Therapeutics director Kush Parmar sells $807,027 in shares

Kush Parmar, a director and 10% owner of Entrada Therapeutics (NASDAQ:TRDA), recently sold $807,027 worth of company shares through 5AM Ventures V, L.P., across two transactions on July 30 and 31, 2026. The sales occurred as TRDA stock surged 24.53% over the past week …

5am Ventures V sells $807,027 of Entrada Therapeutics stock

5AM Ventures V, L.P., a significant owner and director of Entrada Therapeutics (NASDAQ:TRDA), recently sold shares worth $807,027. These transactions occurred over two days, with shares sold at prices between $6.85 and $6.93, even as the stock has surged 24.5% in the past week …

Form 4 Entrada Therapeutics Inc For: 4 August By Investing.com

This article from Investing.com is a minimal announcement regarding a Form 4 filing for Entrada Therapeutics Inc, dated August 4. It provides the stock symbol TRDA and notes a -2.20% change. The content primarily consists of navigation, advertisements, and market data rather than detailed …

Entrada Therapeutics (TRDA) holder sells shares, still reports 1.09M stake

5AM Ventures V, L.P., a ten percent shareholder of Entrada Therapeutics (TRDA), reported selling a total of 116,474 shares of common stock on July 30-31, 2026, with transactions occurring at a weighted average price of $6.93 per share. Despite these sales, affiliated entity 5AM …

Entrada Therapeutics (NASDAQ:TRDA) Director Sells 114,756 Shares

Ventures L.P. 5Am Sells 1,718 Shares of Entrada Therapeutics (NASDAQ:TRDA) Stock

Liquidity Mapping Around (TRDA) Price Events

This article analyzes Entrada Therapeutics Inc. (NASDAQ: TRDA) using AI models, highlighting a positive near-term sentiment within a long-term strength context despite a mid-term weak bias. It identifies key support and resistance levels and outlines three institutional trading strategies (Position, Momentum Breakout, Risk Hedging) …

Entrada Therapeutics Inc (TRDA) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Entrada Therapeutics Inc (TRDA), noting its current valuation score of 6.99 within the Biotechnology & Medical Research industry. It details the company's current P/E ratio of -1.70, highlighting its significant deviation from recent highs and lows. The …

Entrada Therapeutics, Inc. SEC Filing (Jul 30, 2026)

TRDA|Entrada Therapeutics Inc|Price:6.550|Chg%:+0.720

This article provides a comprehensive stock analysis of Entrada Therapeutics Inc (TRDA), highlighting its healthy fundamentals, significant growth potential, and "Buy" ratings from multiple analysts with a highest price target of $18.75. Despite a recent weak stock market performance, the company exhibits strong underlying …

Entrada Therapeutics Inc (TRDA) Institutional Confidence

Entrada Therapeutics Inc (TRDA) has an institutional shareholding score of 7.00, placing it 80th in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 80.65%, showing a 2.92% quarter-over-quarter increase. James Simons is the largest institutional shareholder, holding 0.56% of outstanding …

Entrada Therapeutics Inc (TRDA) Cash Flow

This article provides a detailed historical overview of Entrada Therapeutics Inc's (TRDA) cash flow statements, covering quarterly and annual data for operating, investing, and financing activities. It includes key financial metrics like net income, capital expenditures, and free cash flow, alongside answers to frequently …

Entrada Therapeutics Inc (TRDA) Shareholder Structure: Major Shareholders & Institutional Holdings

This article provides a detailed breakdown of Entrada Therapeutics Inc (TRDA) shareholder structure, listing major shareholders, their equity proportions, and changes in their holdings. It also categorizes shareholders by type (e.g., Investment Advisor, Hedge Fund, Venture Capital) and presents institutional shareholding trends over several …

Entrada Therapeutics Inc (TRDA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a revenue breakdown for Entrada Therapeutics Inc (TRDA), focusing on business segments, regional revenue, and profit contribution. As of the report, relevant data for FY2025 across all quarters and FY2023Q2 have not been disclosed by the company. The currently available regional …

Entrada Therapeutics Inc (TRDA) Financial Health: Profitability & Balance Sheet Analysis

Entrada Therapeutics Inc (TRDA) has a financial score of 6.02, ranking 298 out of 386 in its industry, indicating stable financial status but low operating efficiency. The company reported a significant year-over-year revenue decrease of 95.74% and a net profit decrease of 128.93% in …

Why (TRDA) Price Action Is Critical for Tactical Trading

This article analyzes Entrada Therapeutics Inc. (NASDAQ: TRDA), highlighting weak near and mid-term sentiment despite a long-term positive outlook. It provides AI-generated trading strategies including position, momentum breakout, and risk hedging, along with detailed support, resistance, and signal strength across different time horizons. The …